Drugs that contain Everolimus
1. Drug name - AFINITOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(3 years from now) | |
|
US8410131
(Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(3 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(5 years from now) | |
Treatment: Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progessive neuroendocrine tumors of pancreatic origin (pnet) that are unresectable, locally advanced or metastatic
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
| 7.5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
2. Drug name - AFINITOR DISPERZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8617598
(Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(5 months from now) | |
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 2MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
| 3MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
| 5MG | TABLET, FOR SUSPENSION;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.